

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Use of a substance having oxytocin antagonistic properties for the manufacture of a~~ A medicament for the treatment of a disease relating to oxytocin-induced vascular contractility, comprising a substance having oxytocin antagonistic properties.
2. (Currently Amended) ~~Use of a substance~~ The medicament according to claim 1, wherein said substance is a peptide.
3. (Currently Amended) ~~Use~~ The medicament according to claim 2, wherein said peptide is chosen[, ] from the group ~~comprising~~ consisting of pentapeptides, hexapeptides, heptapeptides, octapeptides, nonapeptides, and decapeptides.
4. (Currently Amended) ~~Use~~ The medicament according to claim 3, wherein said peptide is chosen from the group ~~comprising~~ consisting of atosiban, barusiban, and pharmaceutically acceptable salts thereof.
5. (Currently Amended) ~~Use~~ The medicament according to ~~any one of claims 1-4~~ claim 1, wherein said medicament is comprises an amount of said substance effective for the treatment of hypertension.
6. (Currently Amended) ~~Use~~ The medicament according to claim 5, wherein said medicament is comprises an amount of said substance effective for the treatment of hypertension relating to pregnancy.
7. (Currently Amended) ~~Use~~ The medicament according to ~~any one of claims 1-6~~ claim 1, wherein said oxytocin-induced vascular contractility is present in uterine vessels, vessels in placenta or foetus.
8. (Currently Amended) ~~Use~~ The medicament according to ~~any one of claims 1-5~~ claim 1, wherein said oxytocin-induced vascular contractility is present in vessels in the heart, the kidneys, the brain, the thymus, the pancreas or any other vessels.
9. (Currently Amended) ~~Use~~ The medicament according to ~~any one of claims 1-7~~ claim 1, wherein said medicament is comprises an amount of said substance effective for the treatment of preeclampsia,

intrauterine growth retardation (IUGR), hypoperfusion of the foetus, pregnancy induced hypertension (PIH), toxemia, HELLP syndrome or eclampsia.

10. (Original) A method of treatment comprising administration of a pharmaceutically effective amount of a substance having oxytocin antagonistic properties to a subject suffering from a disease relating to oxytocin-induced vascular contractility.

11. (Original) A method according to claim 10, wherein said substance is a peptide.

12. (Currently Amended) A method according to claim 11, wherein said peptide is chosen from the group ~~comprising~~ consisting of pentapeptides, hexapeptides, heptapeptides, octapeptides, nonapeptides and decapeptides.

13. (Currently Amended) A method according to claim 12, wherein said peptide is chosen from the group ~~comprising~~ consisting of atosiban, barusiban, and pharmaceutically acceptable salts thereof.

14. (Currently Amended) A method according to ~~any one of claims 10-13~~ claim 10, wherein said disease is hypertension.

15. (Original) A method according to claim 14, wherein said hypertension relates to pregnancy.

16. (Currently Amended) A method according to ~~any one of claims 10-15~~ claim 10, wherein said oxytocin-induced vascular contractility is present in uterine vessels, vessels in placenta or foetus.

17. (Currently Amended) A method according to ~~any one of claims 10-14~~ claim 10, wherein said oxytocin-induced vascular contractility is present in the heart, the kidney, the brain, the thymus, the pancreas or any other vessels.

18. (Currently Amended) A method according to ~~any one of claims 10-16~~ claim 10, wherein said disease is preeclampsia, intrauterine growth retardation (IUGR), hypoperfusion of the foetus, pregnancy induced hypertension (PIH), toxemia, HELLP syndrome or eclampsia.

19. (Currently Amended) A method according to ~~any one of claims 10-18~~ claim 10, wherein said subject is a human.